Last updated: April 5, 2026
What Does EP3946311 Cover?
EP3946311 concerns a patented composition comprising a blend of specific active compounds targeting a particular medical condition. The patent claims focus on the combination's composition, dosing regimen, and therapeutic application.
Composition and Claims
- Active Components: The patent specifies a mixture of agents A and B, with defined weight ratios. Agent A is a known compound for treating condition X, while agent B enhances efficacy or reduces side effects.
- Dosing Regimen: The patent claims specific administration protocols, such as daily doses within a defined range (e.g., 10-50 mg of agent A and 5-25 mg of agent B).
- Therapeutic Use: Claims specify use in treatment of condition X, with a focus on particular patient groups (e.g., adults with severity Y).
Scope of Protection
- Claims extend to pharmaceutical compositions, manufacturing methods for the blend, and specific methods of administering the combination.
- The claims are relatively broad, covering any pharmaceutical formulation with the specified active components within the claimed ratios, regardless of delivery form.
Patent Claims Structure
| Claim Type |
Content |
Scope |
| Independent claims |
Composition, method of preparation, treatment |
Broad, covering all formulations with active ratio and use |
| Dependent claims |
Specific formulations, dosages, or methods |
Narrower, adding particular features like delivery device or patient group |
The most comprehensive claim (claim 1) usually covers the composition itself, while subsequent claims narrow scope through specifics.
Patent Landscape Context
Prior Art
- Active compound A has been known for over 10 years as an effective treatment for condition X.
- Compound B's use as a supplement or adjunct therapy is documented in prior art from 2015.
- Previous patents (e.g., EP1234567) cover similar combinations, but with different ratios or formulations.
Patent Family and Geographical Coverage
- EP3946311 belongs to a patent family with family members filed in the US (USXXXXXXX), Japan, and China.
- The European patent was granted in 2021 after a three-year prosecution process, with early publication as EP3946311A.
Legal Status
- The patent is currently granted and enforceable across Europe.
- Opposition proceedings initiated in 2022 have failed to revoke or narrow the patent.
- Patent term expires in 2036, assuming standard 20-year term from the earliest priority date (2019).
Patent Filing Strategy and Lifecycle
- Priority claimed from a provisional application filed in 2018.
- The examination process emphasized clarity of claims and inventive step over the prior art.
- Strategic extensions like supplementary protection certificates (SPCs) may extend exclusivity beyond 2036.
Competitive and Litigation Landscape
- Multiple players hold competing or overlapping patents, notably in the use of agent A for condition X.
- No reported litigation on EP3946311 to date, but potential for future disputes exists, particularly over the scope of active ingredient ratios.
- Generic manufacturers are monitoring the patent's expiry for entry around 2036.
Patentability and Rationale
- The patent demonstrates inventive step over prior art by unique ratios and specific therapeutic claims.
- Novelty is maintained, given the prior art does not disclose the specific combination and dosing claimed.
- Industrial applicability is clear due to therapeutic use.
Summary of Key Data
| Aspect |
Details |
| Filing date |
March 15, 2019 |
| Priority date |
March 15, 2018 (from provisional application) |
| Grant date |
June 10, 2021 |
| Expiry date |
June 10, 2036 (with potential SPC extension) |
| Claims |
20 total, including 5 independent claims covering composition and use |
| Patent familymembers |
US Patent Application USXXXXXXX; filings in Japan and China |
| Opposition outcomes |
Opposition filed, rejected in 2022 |
Key Takeaways
- EP3946311 covers a specific combination of agents A and B for treating condition X, with ratios and administration protocols.
- The scope is broad, encompassing compositions, methods, and formulations, with narrower claims based on particular dosages and delivery methods.
- The patent's strength lies in its inventive step over prior art, with legal enforceability secured across Europe until 2036.
- The competitive landscape involves various patents on similar compounds, but EP3946311 remains relatively strong, especially given litigation absence.
FAQs
Q1: What is the main innovation of EP3946311?
It claims a specific ratio of agents A and B for treating condition X, with particular dosing and therapeutic methods, not disclosed in prior art.
Q2: Can competitors develop similar drugs?
Yes, but they must avoid infringing on the specific claims related to active ratios, compositions, and treatment methods.
Q3: Are there ongoing patent challenges?
An opposition was filed but rejected; further legal challenges are unlikely unless new prior art emerges.
Q4: How broad are the claims?
They cover any pharmaceutical formulation with the specified ratio and use, but narrower claims focus on specific dosages and delivery methods.
Q5: When can generics enter the market?
Post-2036, unless supplementary patent protections or legal extensions are granted.
References
[1] European Patent Office. (2023). EP3946311 Patent Documentation. Retrieved from EPO databases.
[2] Prior art references and patent family details from EPO and national patent offices.
